• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Epistaxis Severity in Pediatric HHT Patients Is Typically Mild

by Amy E. Hamaker • July 8, 2018

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

How do epistaxis onset and severity present in pediatric hereditary hemorrhagic telangiectasia (HHT) patients in terms of age of onset within genetic subtypes?

Bottom line
Epistaxis may present early in HHT, but is typically mild in the pediatric period and is slightly worse in patients with HHT1.

You Might Also Like

  • Avastin Treatment for Hereditary Hemorrhagic Telangiectasia Epistaxis
  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia?
  • Can Tonsil Size Help Predict Pediatric OSA Severity?
Explore This Issue
July 2018

Background: HHT is an autosomal dominant disorder of vascular formation that has multiple genetic subtypes, with HHT type 1 and HHT type 2 making up the majority of cases. HHT-associated vascular lesions include telangiectases and arteriovenous malformations (AVMs), and epistaxis is the most common HHT symptom. Reports of epistaxis onset in childhood have largely relied on adult patient recall, and there are no reports to date of epistaxis severity in the pediatric HHT population. Early HHT detection allows for solid organ screening for AVMs and treatment to avoid potentially catastrophic complications.

Study design: Retrospective cohort chart review of 69 patients aged 0 to 18 years with a clinical or genetic HHT diagnosis who were evaluated at a tertiary multidisciplinary HHT clinic from January 2010 to June 2016.

Setting: University of Utah HHT Center, Salt Lake City.

Synopsis: Sixty patients had HHT confirmed by genetic testing, and nine (from families with known mutations) met published clinical diagnostic criteria alone. All patients had a family history of HHT. Over 90% of patients had either HHT2 or HHT1. The mean patient age at evaluation was 9 years, and the median epistaxis onset age was 5 years. Patients with HHT1 had a younger median epistaxis onset age at 3 years (versus 5 years in HHT2). Ten subjects had not yet developed epistaxis. The majority of patients with epistaxis experienced mild bleeding; none experienced severe nosebleeds. Anemia was noted in only two patients, and no blood transfusion treatment were required. Four patients sought medical attention for their nosebleeds. There was no difference in the number of clinical diagnostic criteria in patients with HHT1 versus HHT2, but the slightly higher HHT1 score was statistically significant after adjusting for age and sex. Median epistaxis severity scores were higher in HHT1, while epistaxis frequency and duration tended to be lower in HHT2. Limitations included a lack of routine rhinoscopy during evaluation and ascertainment bias due to HHT specialty clinic evaluation.

Citation: Gonzalez CD, McDonald J, Stevenson DA, et al. Epistaxis in children and adolescents with hereditary hemorrhagic telangiectasia. Laryngoscope. November 24, 2017. Doi: 10.1002/lary.27015.

Filed Under: Literature Reviews, Pediatric Tagged With: epistaxis, HHT, pediatric patients, pediatricsIssue: July 2018

You Might Also Like:

  • Avastin Treatment for Hereditary Hemorrhagic Telangiectasia Epistaxis
  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia?
  • Can Tonsil Size Help Predict Pediatric OSA Severity?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Do you use AI-powered scribes for documentation?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • History of the Cochlear Implant

    • Keeping Watch for Skin Cancers on the Head and Neck

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • ENTtoday Recognized for Excellence
    • The Importance of Time Away
    • Endoscopic Ear Surgery: Advancements and Adoption Challenges 
    • Reflections from a Past President of the Triological Society
    • ENT Surgeons Explore the Benefits and Challenges of AI-Powered Scribes: Revolutionizing Documentation in Healthcare

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939